Shire eating disorder drug gets U.S. priority review

LONDON, Sept 15 (Reuters) - Shire's hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems.